The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Alexander A. Firsov

Address correspondence to Alexander A. Firsov

[email]@dol.ru

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Address correspondence to Alexander A. Firsov. 2012
  • Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Russia. 2002 - 2008
  • Department of Pharmacokinetics, Center for Science and Technology LekBioTech, Moscow, Russia. 1999 - 2002

References

  1. Comparative Pharmacodynamics and Antimutant Potentials of Doripenem and Imipenem with Ciprofloxacin-Resistant Pseudomonas aeruginosa in an In Vitro Model. Firsov, A.A., Gilbert, D., Greer, K., Portnoy, Y.A., Zinner, S.H. Antimicrob. Agents Chemother. (2012) [Pubmed]
  2. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Firsov, A.A., Smirnova, M.V., Strukova, E.N., Vostrov, S.N., Portnoy, Y.A., Zinner, S.H. Int. J. Antimicrob. Agents (2008) [Pubmed]
  3. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Firsov, A.A., Lubenko, I.Y., Smirnova, M.V., Strukova, E.N., Zinner, S.H. Antimicrob. Agents Chemother. (2008) [Pubmed]
  4. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. Firsov, A.A., Smirnova, M.V., Lubenko, I.Y., Vostrov, S.N., Portnoy, Y.A., Zinner, S.H. J. Antimicrob. Chemother. (2006) [Pubmed]
  5. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Firsov, A.A., Alferova, I.V., Smirnova, M.V., Lubenko, I.Y., Portnoy, Y.A., Zinner, S.H. Int. J. Antimicrob. Agents (2005) [Pubmed]
  6. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Firsov, A.A., Lubenko, I.Y., Vostrov, S.N., Portnoy, Y.A., Zinner, S.H. Antimicrob. Agents Chemother. (2005) [Pubmed]
  7. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Firsov, A.A., Vostrov, S.N., Lubenko, I.Y., Zinner, S.H., Portnoy, Y.A. Int. J. Antimicrob. Agents (2004) [Pubmed]
  8. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Firsov, A.A., Vostrov, S.N., Lubenko, I.Y., Portnoy, Y.A., Zinner, S.H. Int. J. Antimicrob. Agents (2004) [Pubmed]
  9. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. Firsov, A.A., Vostrov, S.N., Lubenko, I.Y., Arzamastsev, A.P., Portnoy, Y.A., Zinner, S.H. J. Antimicrob. Chemother. (2004) [Pubmed]
  10. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Firsov, A.A., Vostrov, S.N., Lubenko, I.Y., Drlica, K., Portnoy, Y.A., Zinner, S.H. Antimicrob. Agents Chemother. (2003) [Pubmed]
  11. Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. Firsov, A.A., Zinner, S.H., Vostrov, S.N., Kononenko, O.V., Portnoy, Y.A., Shustova, L.V., Kadenatsi, I.B. J. Antimicrob. Chemother. (2002) [Pubmed]
  12. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. Firsov, A.A., Zinner, S.H., Vostrov, S.N., Portnoy, Y.A., Lubenko, I.Y. J. Antimicrob. Chemother. (2002) [Pubmed]
  13. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Firsov, A.A., Zinner, S.H., Lubenko, I.Y., Portnoy, Y.A., Vostrov, S.N. Chemotherapy (2002) [Pubmed]
  14. Use of Modeling Techniques to Aid in Antibiotic Selection. Firsov, A.A., Zinner, S.H. Curr. Infect. Dis. Rep (2001) [Pubmed]
  15. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Firsov, A.A., Lubenko, I.Y., Portnoy, Y.A., Zinner, S.H., Vostrov, S.N. Antimicrob. Agents Chemother. (2001) [Pubmed]
  16. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. Firsov, A.A., Lubenko, I.Y., Vostrov, S.N., Kononenko, O.V., Zinner, S.H., Portnoy, Y.A. J. Antimicrob. Chemother. (2000) [Pubmed]
  17. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Firsov, A.A., Zinner, S.H., Lubenko IYu, , Vostrov, S.N. Int. J. Antimicrob. Agents (2000) [Pubmed]
  18. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Firsov, A.A., Vostrov, S.N., Kononenko, O.V., Zinner, S.H., Portnoy, Y.A. Antimicrob. Agents Chemother. (1999) [Pubmed]
  19. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. Firsov, A.A., Vasilov, R.G., Vostrov, S.N., Kononenko, O.V., Lubenko, I.Y., Zinner, S.H. J. Antimicrob. Chemother. (1999) [Pubmed]
 
WikiGenes - Universities